Table 2.
List of studies investigating the performances of NMP22 tests in surveillance setting in non-muscle invasive bladder cancer patients
| Marker | Author (year) reference | Study design | No. of patients | Sensitivity (%) | Specificity (%) | Other end points |
|---|---|---|---|---|---|---|
| NMP22 BladderChek | Aguilera Tubet (2005) [65] | Cohort/marker comparison | 88 | 28 | 93.55 | – |
| Grossman (2006) [66] | Cohort prospective | 668 | 49.5 | 87.3 | NPV 90.5% | |
| Kumar (2006) [67] | Cohort | 131 | 85 | 77 | PPV 67.2%, NPV 90.4% | |
| Gonzalo Rodriguez (2008) [68] | Cohort | 109 | 25 | 91.1 | PPV 18.2%, NPV 93.9% | |
| Gupta (2009) [69] | Cohort prospective | 145 | 85.7 | 77.5 | PPV 70.6%, NPV 89.6%. association with rec | |
| Kundal (2010) [70] | Cohort | 115 | 81.3 | 92 | – | |
| Choi (2010) [71] | Cohort | 262 | 72.7 | 91.7 | – | |
| Hwang (2011) [72] | Cohort | 597 | 22.6 | 97.9 | – | |
| Coskuner (2012) [73] | Cohort | 95 | 44.4 | 98.4 | PPV 80%, NPV 92.6% | |
| Önal (2015) [74] | Cohort/case control | 65 | 85.4 | 76.5 | – | |
| Yafi (2015) [17] | Marker-comparison prospective | 109 | 58 | 85 | – | |
| Bell (2016) [18] | Marker-comparison prospective | 91 | – | – | Association with RFS and PFS | |
| Lotan (2017) [7] | Marker-comparison prospective | 803 | 11 | – | NPV 86% | |
| Pichler (2017) [19] | Marker-comparison prospective | 75 | 12.9 | 100 | PPV 100%, NPV 61.9% | |
| NMP22 | Serretta (1998) [75] | Cohort | 137 | 71 | 61 | PPV 44.7%, NPV 83% |
| Witjes (1998) [76] | Cohort | 50 | 75 | 82 | PPV 56%, NPV 91% | |
| Serretta (2000) [77] | Marker-comparison prospective | 179 | 74 | 55 | PPV 42.2%, NPV 83% | |
| Chahal (2001) [78] | Cohort | 115 | 24 | 92 | PPV 33%, NPV 87% | |
| Giannopoulos (2001) [79] | Marker-comparison prospective | 95 | 56 | – | – | |
| Shariat (2004) [80] | Cohort/case control | 302/42 | 66 (cut-off 6.5 U/ml) 54 (cut-off 10 U/ml) | 73 (cut-off 6.5 U/ml) 85 (cut-off 10 U/ml) | Prediction of BCa (OR 1.5) | |
| Aguilera Tubet (2005) [65] | Cohort/marker comparison | 88 | 35 | 80.3 | – | |
| Lahme (2005) [81] | Cohort/case control prospective | 164/64 | 62 | 65.9 | – | |
| Kibar (2006) [82] | Cohort/case control marker comparison | 60/30 | 73 | 89.7 | – | |
| Raina (2008) [83] | Cohort (atypical cytology) | 71 | 81 | 89.3 | PPV 92%, NPV 76% | |
| Mansoor (2008) [84] | Cohort | 94 | 45 | 100 | PPV 100%, NPV 87% | |
| Horstmann (2009) [85] | Cohort | 221 | 68 | 49 | PPV 57%, NPV 60% | |
| Shariat (2011) [20] | Cohort (negative cytology) | 2222 | – | – | Association with Rec and Prog | |
| Doğan (2013) [86] | Cohort | 49 | 33 | 76 | PPV 31%, NPV 78% | |
| Lotan (2017) [7] | Marker-comparison prospective | 803 | 26 | – | NPV 86% |
PPV positive predictive value, NPV negative predictive value, Rec recurrence, Prog progression, RFS recurrence-free survival, PFS progression-free survival